Dovitinib’s mechanism of action involves downregulating the stem cell protein Lin28 and its target HMGA2 (High-Mobility Group Protein A2), affecting the STAT3/LIN28/Let-7/HMGA2 regulatory axis in GBM cells [104]. The gene discussed is LIN28A; the disease is glioblastoma.